Continue teclistamab for a limited time in responding patients
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This Phase 2 trial looks at stopping or limiting teclistamab after you’ve already had a good ongoing response. It aims to see if people can safely continue to benefit while using the medicine for a shorter time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 18 years old and able to sign consent forms
- You started teclistamab (first full dose) about 6 to 9 months ago, and you’ve been receiving enough dose regularly since then
- You had a teclistamab dose within the last 4 weeks
- You had measurable disease when teclistamab started, and you achieved a very good response (VGPR or better) that is still ongoing (no progression)
- Before starting teclistamab, you previously received all of these: a proteasome inhibitor, a lenalidomide/pomalidomide-type medicine, and an anti-CD38 antibody; and either you had 3+ prior treatment lines or you were not responding to both a proteasome inhibitor and a thalidomide-type medicine
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination for multiple myeloma that has come back or not responded to earlier treatments. It uses a drug called teclistamab (which helps your immune system attack myeloma cells) along with an infusion of your own immune cells (lymphocytes) to potentially improve the response.
This study looks at how well two newer medicines, teclistamab and talquetamab, work in people with multiple myeloma that has come back or stopped responding to several treatments. If you qualify, you may be able to receive one of these medicines as part of your regular care.
This trial tests whether adding teclistamab to lenalidomide (or using teclistamab alone) helps keep newly diagnosed multiple myeloma from coming back after an autologous stem cell transplant. It’s comparing these options to lenalidomide alone as long-term maintenance.
This trial tests a lower dose of the drug teclistamab in people newly diagnosed with multiple myeloma. It aims to see if a lower dose is still effective and has fewer side effects.
This trial tests a new combination of two drugs, teclistamab and pomalidomide, given in an alternating schedule, for people with multiple myeloma that has relapsed or become resistant to standard treatments. The goal is to see if this combination helps control the cancer and is safe to take.
This Phase 2 study tests a study treatment in adults with multiple myeloma that needs treatment. It may help by trying to improve disease control after you’ve had (or are scheduled to have) standard therapy like chemotherapy and stem cell transplant for some people.
Hear when a new Myeloma Multiple trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.